Immunosuppressive

Samsung Bioepis HUMIRA Biosimilar Approved in the U.S. & Will be Available in June 2023 Due to Patent Thicket

Jul 27, 2019 | Autoimmune Disorder, Biosimilars, Humira, Immunosuppressive, Korea, Monoclonal Antibody

Samsung Bioepis Co. Ltd. reports that the U.S. FDA has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult...

Biologics Associated with 34,000 Deaths Since 2004: What Are the Implications?

Jul 18, 2019 | Biologic Drugs, Biologics, Immunosuppressive

Costly Biologics to treat diseases such as autoimmune diseases have flooded the market over the past couple of decades. Prominently advertised on television ads promising improved gastrointestinal symptoms or clearer skin with “sexy elbows.” They are effective for...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Samsung Bioepis HUMIRA Biosimilar Approved in the U.S. & Will be Available in June 2023 Due to Patent Thicket

Biologics Associated with 34,000 Deaths Since 2004: What Are the Implications?

Pin It on Pinterest